ArticleEuropean journal of haematology2020

Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.

Frederick W Thielen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.